Earnings Call Summary | Theratechnologies(THTX.US) Q2 2024 Earnings Conference
Earnings Call Summary | Theratechnologies(THTX.US) Q2 2024 Earnings Conference
The following is a summary of the Theratechnologies Inc. (THTX) Q2 2024 Earnings Call Transcript:
以下是Theratechnologies公司（THTX）2024年第二季度業績會議通話記錄摘要：
Financial Performance:
金融業績：
Theratechnologies reported second quarter revenue at $22 million, a 25% year-over-year growth.
Recorded $5.5 million of adjusted EBITDA, reflecting a 25% margin.
The company became net income positive for the first time in recent history, reporting a net profit of around $1 million, or $0.02 per share.
Projected annual revenues for the full year 2024 are reaffirmed to be between $87 million and $90 million, with an adjusted EBITDA forecast of $13 million to $15 million.
Theratechnologies報告第二季度營收爲2200萬美元，同比增長25％。
調整後的EBITDA爲550萬美元，反映出25％的利潤率。
該公司近期歷史上首次實現淨收益，報告淨利潤約100萬美元，每股收益爲0.02美元。
2024年全年預計營收將保持在8700萬美元至9000萬美元之間，調整後EBITDA預計爲1300萬至1500萬美元。
Business Progress:
業務進展：
Achieved a year-to-date increase of 13% in new enrollments and 16% in unique patients for EGRIFTA SV.
Fully enrolled the second cohort in the Phase 1 clinical trial of sudocetaxel zendusortide, showing signs of durable disease stabilization and efficacy in treating solid tumors.
Pursuing potential partners for additional development steps for oncology programs and overall SORT1+ technology platform.
EGRIFTA SV的新入職人數和獨特患者增長率均達到13％和16％。
在固體腫瘤治療中，已完成蘇多司他胺合成物的第二期臨床試驗，顯示出持久的疾病穩定和療效跡象。
尋求潛在合作伙伴，爲腫瘤學項目和整體SORT1+技術平台開展額外的開發步驟。
Opportunities:
機會：
Increased demand for treatments addressing central adiposity underpinned by market dynamics around weight loss driven by GLP-1.
Exploring business development opportunities, including acquisitions and commercial partnerships that complement existing business drivers.
由於有關減肥的市場動態帶動了GLP-1驅動的市場，治療中心性脂肪過剩的需求增加。
探索商業發展機會，包括對現有業務驅動程序的補充，以及收購和商業合作伙伴關係。
Risks:
風險：
Faced competitive pressures with Trogarzo, leading to a 13.4% year-over-year reduction in its net sales due to lower unit sales as it lost market share to new entrants in the multi-drug resistant segment of HIV treatment.
面對Trogarzo的競爭壓力，由於在多藥耐藥性HIV治療的新參與者中失去市場份額，其淨銷售額同比下降13.4％。
More details: Theratechnologies IR
更多詳細信息：Theratechnologies IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。